New Technologies in Type 1 and Type 2 Diabetes Management

As well established as the practices are for the management of types 1 and 2 diabetes, a raft of new technologies, from modest to radical, are steadily entering clinical practice and the industry, according to a new report from MedMarket Diligence.
Spread the Word
Listed Under

Blood Glucose


California - US

Aug. 16, 2010 - PRLog -- The diagnosis, monitoring and management of both insulin-dependent diabetes mellitus (also known as Type 1) and non-insulin dependent diabetes mellitus (aka Type 2) is a well established practice of regulating blood glucose levels.  Nonetheless, manufacturers have steadily developed new technologies that continue to improve the management of the disease by reducing burden on patients, reducing the incidence of diabetes-related complications and reducing the overall cost of the disease on healthcare systems.

“Without a doubt, the 10-year study known as Diabetes Control and Complications Trial, or DCCT, played an enormous role in validating the technologies that now routinely serve to improve the quality of life for diabetics,” says Patrick Driscoll, President of the medical technology business research firm MedMarket Diligence. “But the steady growth in diabetes prevalence worldwide, driven by increased prevalence of obesity, demographic trends and other forces, combined with persistent demand for ever less intrusive monitoring technologies and better long-term blood glucose management, creates an enormous opportunity for new technology development by diabetes product manufacturers.”

According to Driscoll, and detailed in the MedMarket Diligence report (see, products in diabetes management represent an enormous $36 billion global market annually, encompassing insulin, blood glucose meters, lancets, test strips, insulin pumps, syringes (and other delivery devices), continuous blood glucose meters and a broad range of anti-diabetic drugs (oral hypoglycemic agents). Each of these product areas has many competitors offering and developing new products (even the area of insulin has a dozen competing companies), with a steady stream of innovations being introduced to the market and clinical practice.  Moreover, aggressive research has continued to push for more advanced solutions to diabetes, including novel insulin delivery methods, pancreas transplants, islet cell transplants, stem cell approaches, antibody treatment, vaccines, novel drugs, new continuous blood glucose monitoring systems and the “holy grail” of diabetes management, a closed-loop blood glucose monitoring and insulin pump system (sometimes referred to as an “artificial pancreas”), which may be approved for marketing in the very near future.

Growth in the market for diabetes management products ranges globally from a low of about 11% annually in Europe to nearly 24% annually in Asia. Overall, the U.S. and Europe, with their advanced healthcare markets and payment systems, still represent an aggregate 68% of the global market.  By product area, the segments driving the largest annual revenues are insulins and anti-diabetic drugs, comprising almost two thirds of the global sales of diabetes management products.

The MedMarket Diligence report #D510, “Products, Technologies, Markets and Opportunities in Diabetes Management Worldwide, 2009-2018,” details the worldwide incidence and prevalence by country/region of Type 1 and Type 2 diabetes and details the current and projected market for diagnostic and therapeutic products in the management of diabetes, including anti-diabetic drugs, alternative insulin types, blood glucose monitoring (including continuous monitoring devices), insulin pumps, and other established and emerging products in diabetes management.  The report provides an emphasis of detail on the status of development of novel products including noninvasive monitoring, oral/inhaled/other insulin delivery. The report details the clinical and technology developments underlying this huge and evolving worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.  Separate size, growth and competitor share data are presented for the U.S., European, Asia/Pacific and Rest of World.  The report profiles active companies including detailed profile information on major competitors, brief profiles of companies with less sizeable current or potential positions in the market, plus additional profiles of companies with novel or advanced research activities in the market.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

The report is described, with complete table of contents and list of exhibits at and may be accessed for immediate download via

# # #

MedMarket Diligence provides data and insight to the medical products, investment and other industries on advanced medical technologies through focused medical technology market and assessment Reports and the Medtech Startups Database.
Email:*** Email Verified
Tags:Diabetes, Insulin, Blood Glucose, Diabetic, Hba1c
Industry:Medical, Reports, Business
Location:California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
MedMarket Diligence, LLC PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share